Thanks to the introduction of smokable marijuana products in Florida, Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) reported record-breaking Q2 revenues as its lead in the state increases.

On Thursday (August 15), the multi-state operator (MSO) reported revenue of US$57.9 million during its Q2 2019, which represents a 30 percent quarter-over-quarter growth.

Trulieve confirmed a patient count increase of 19 percent in Florida during the quarter, bringing its total number of patient consumers to 181,000.

In March, the state of Florida lifted a ban on smokable marijuana products, a decision that has also lifted the consumer volume for the market. Currently, Florida is only a medically legal marijuana state.

Trulieve reported that dried marijuana represented half of its sold products in Florida during the quarter when compared to approximately 30 percent in its previous quarter.

At the end of Thursday’s trading session, the company closed with a price of C$12.55, representing a drop of 2.37 percent in value per share.

Trulieve’s substantial revenue growth also helped it reach a net income of US$57.5 million for the quarter.

Investors of the company noticed an earning per share of US$0.52 during Q2 2019. As for the six-month period ended June 30, the company reported gains per share of US$0.66.

According to the analyst data aggregator site TipRanks, Trulieve holds an average “strong buy” rating based on three analyst ratings. The average price per share from analysts is C$31.

During a call with investors and analysts, Kim Rivers, CEO of the company, confirmed that Trulieve dispenses 52 percent of the flowers sold in the state, according to data from the Office of Medical Marijuana Use (OMMU), the state’s marijuana regulatory agency.

A research note from Canaccord Genuity indicated the second closest competitor in terms of market share for dried flower sold in Florida is Curaleaf Holdings (CSE:CURA,OTCQX:CURLF) with a 17.9 percent share.

Canaccord indicated that Trulieve, Curaleaf and Liberty Health Sciences (CSE:LHS,OTCQX:LHSIF) represent 85 percent of the entire dried flower market in the state.

Trulieve operates 30 stores in Florida, and, according to Rivers, 14 additional stores are planned to be opened before the end of the year.

As of Tuesday (August 13), there are 150 marijuana shops in Florida, according to OMMU data.

The state of Florida has proven to be an attractive market for cannabis MSOs, which look to expand the exposure of the US cannabis stock market. Florida is set to gain more attention from investors as additional MSOs begin to lay out expansion plans in the state.

As part of its Q4 2018 and year-end results, Curaleaf largely credited Florida for the bump in its financials. Fellow MSO Columbia Care (NEO:CCHW,OTCQX:CCHWF) announced it plans to open 20 dispensaries in the state before the end of 2019.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company” or “Lexaria”), a global innovator in drug delivery platforms, is pleased to announce the appointment of Mr. Al Reese, Jr., to its Board of Directors

Mr. Reese has over 40 years experience in public and private businesses including as CFO of a formerly Nasdaq-listed energy company where he arranged finance transactions totaling over $10 billion dollars during his 20-year tenure. Mr. Reese was a Director and Chairman of the Audit Committee of a community bank in Texas for ten years until such time as it was acquired by a larger banking group in 2018.

Keep reading... Show less

Mexico looks to be closer than ever to cannabis reform, with the country releasing its regulation plans to make the drug legal in medical settings.

Meanwhile, despite the financial hardships seen recently in the Canadian cannabis market, CEOs in the country are still receiving top dollar, as per a new study.

Keep reading... Show less

Not for Distribution to United States Newswire Services or for Dissemination in the United States

Cresco Labs (CSE:CL) (OTCQX:CRLBF) (“Cresco” or the “Company”), one of the largest vertically integrated multistate cannabis operators in the United States, announced today the pricing of its previously announced best efforts overnight marketed offering (the “Offering”) of subordinate voting shares (the “Offered Securities”) of the Company at a price of C$16.00 per share for a total gross proceeds of approximately US$125 Million. The issue price represents a 3.3% discount to the last close of the Company’s subordinate voting shares traded on the Canadian Securities Exchange as of January 14, 2021. 100% of the Offering is expected to be purchased by a total of seven new and existing institutional investors, including current shareholder, Wasatch Global Investors.

Keep reading... Show less

Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from leaders at: Tilray, Inc. (NASDAQ: TLRY), Icanic Brands (OTC: ICNAF) (CSE: ICAN) Red Light Holland (OTC: TRUFF) (CSE: TRIP) and Aphria, Inc. (NASDAQ: APHA).

Investors are cheering new and expected legislation which is opening new market opportunities for both cannabis and psychedelics globally. Innovation in premium branding, growing technologies, manufacturing, with operational execution are key, in the drive towards profitability. Wall Street Reporter highlights the latest comments from industry thought leaders in cannabis and psychedelics:

Keep reading... Show less

Lexaria Bioscience Corp. (NASDAQ:LEXX)(NASDAQ:LEXXW)(CSE:LXX) (the “Company”) today announced the closing of its previously announced underwritten public offering (the “Offering”) of 1,828,571 units, each unit consisting of one share of common stock and one warrant to purchase one share of common stock at a public offering price of $5.25 per unit (all prices in US$). The warrants have an exercise price of $6.58 per share, are immediately exercisable and will expire five years following the date of issuance. In connection with the Offering, the underwriter exercised in full its option to purchase an additional 274,285 shares of common stock and additional warrants to purchase 274,285 shares of common stock. The gross proceeds from the Offering were approximately $11.04 million, before deducting underwriting discounts and estimated offering expenses. No securities were offered or sold in Canada, including through the CSE or any other trading market in Canada

H.C. Wainwright & Co. (“Wainwright”) acted as the sole book-running manager for the Offering and is a non-related party to the Company.

Keep reading... Show less